MX345042B - Composiciones y métodos para tratamiento no quirúrgico de ptosis. - Google Patents

Composiciones y métodos para tratamiento no quirúrgico de ptosis.

Info

Publication number
MX345042B
MX345042B MX2013009597A MX2013009597A MX345042B MX 345042 B MX345042 B MX 345042B MX 2013009597 A MX2013009597 A MX 2013009597A MX 2013009597 A MX2013009597 A MX 2013009597A MX 345042 B MX345042 B MX 345042B
Authority
MX
Mexico
Prior art keywords
compositions
oxymetazoline
ptosis
methods
surgical treatment
Prior art date
Application number
MX2013009597A
Other languages
English (en)
Other versions
MX2013009597A (es
Inventor
M D Silverberg Mark
Original Assignee
Voom Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voom Llc filed Critical Voom Llc
Publication of MX2013009597A publication Critical patent/MX2013009597A/es
Publication of MX345042B publication Critical patent/MX345042B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen composiciones farmacéuticas y métodos de uso de las composiciones, para el tratamiento no quirúrgico de ptosis (caída de párpados). En una modalidad, la composición incluye oximetazolina al 0.1% formulada para administración tópica a un ojo. En una modalidad, la composición incluye una combinación sinergística de oximetazolina y fenilefrina, formulada para administración tópica a un ojo. La oximetazolina sola no causa dilatación de la pupila (midriasis), y una combinación sinergística de oximetazolina y fenilefrina no induce midriasis clínicamente significativa. Además de proveer efectos cosméticos deseados, las composiciones y métodos de la invención pueden mejorar los campos visuales de otra manera comprometidos por ptosis.
MX2013009597A 2011-03-03 2012-02-24 Composiciones y métodos para tratamiento no quirúrgico de ptosis. MX345042B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis
PCT/US2012/026496 WO2012118704A1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis

Publications (2)

Publication Number Publication Date
MX2013009597A MX2013009597A (es) 2014-01-08
MX345042B true MX345042B (es) 2017-01-16

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009597A MX345042B (es) 2011-03-03 2012-02-24 Composiciones y métodos para tratamiento no quirúrgico de ptosis.

Country Status (23)

Country Link
US (8) US20120225918A1 (es)
EP (2) EP2680829B1 (es)
JP (1) JP6106100B2 (es)
KR (1) KR101889392B1 (es)
CN (1) CN103501771B (es)
AU (1) AU2012223615B2 (es)
BR (1) BR112013022094A2 (es)
CA (1) CA2827285C (es)
CY (1) CY1122565T1 (es)
DK (1) DK2680829T3 (es)
ES (1) ES2750123T3 (es)
HR (1) HRP20192266T1 (es)
HU (1) HUE046740T2 (es)
LT (1) LT2680829T (es)
MX (1) MX345042B (es)
PL (1) PL2680829T3 (es)
PT (1) PT2680829T (es)
RS (1) RS59636B1 (es)
RU (1) RU2582392C2 (es)
SG (1) SG192801A1 (es)
SI (1) SI2680829T1 (es)
WO (1) WO2012118704A1 (es)
ZA (1) ZA201307262B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2014182610A2 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
EP3860592A4 (en) * 2018-11-26 2023-04-19 Cellix Bio Private Limited OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND EYE DISEASES
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
JP2023522953A (ja) * 2020-04-23 2023-06-01 オコジェン、インコーポレイテッド ウイルス性結膜炎の処置
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
AU7081598A (en) * 1997-04-24 1998-11-13 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
PL373033A1 (en) * 2002-06-20 2005-08-08 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
JP5275214B2 (ja) 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
US8466203B2 (en) 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
PT2408453T (pt) * 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
WO2010141831A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
CN103140217B (zh) 2010-08-06 2015-08-19 盖尔德马研究及发展公司 用于治疗或预防皮肤病的化合物的组合
EP3181121B1 (en) 2010-12-03 2020-10-28 EPI Health, LLC Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
EP3578178A1 (en) * 2011-02-15 2019-12-11 Aclaris Therapeutics, Inc. Pharmaceutical composition comprising oxymetazoline
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
KR20150011807A (ko) 2012-05-25 2015-02-02 질리어, 인크. 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
HRP20192266T1 (hr) 2020-03-20
HUE046740T2 (hu) 2020-03-30
US20180338953A1 (en) 2018-11-29
CY1122565T1 (el) 2021-01-27
JP6106100B2 (ja) 2017-03-29
PT2680829T (pt) 2019-12-10
SI2680829T1 (sl) 2020-02-28
EP3653205A2 (en) 2020-05-20
BR112013022094A2 (pt) 2017-06-27
KR20140013013A (ko) 2014-02-04
US8357714B2 (en) 2013-01-22
JP2014506927A (ja) 2014-03-20
LT2680829T (lt) 2019-12-27
WO2012118704A1 (en) 2012-09-07
NZ614719A (en) 2015-05-29
CN103501771B (zh) 2016-05-11
US20120225920A1 (en) 2012-09-06
CA2827285A1 (en) 2012-09-07
AU2012223615A1 (en) 2013-10-24
US10912765B2 (en) 2021-02-09
US9018240B2 (en) 2015-04-28
US20120225919A1 (en) 2012-09-06
ZA201307262B (en) 2015-02-25
DK2680829T3 (da) 2019-11-18
EP3653205A3 (en) 2020-08-26
SG192801A1 (en) 2013-09-30
MX2013009597A (es) 2014-01-08
PL2680829T3 (pl) 2020-03-31
US20120225918A1 (en) 2012-09-06
US20220218669A1 (en) 2022-07-14
US20160038465A1 (en) 2016-02-11
RU2013142602A (ru) 2015-04-10
RU2582392C2 (ru) 2016-04-27
EP2680829B1 (en) 2019-09-25
AU2012223615B2 (en) 2017-03-02
ES2750123T3 (es) 2020-03-25
CN103501771A (zh) 2014-01-08
US20200009114A1 (en) 2020-01-09
US9867808B2 (en) 2018-01-16
RS59636B1 (sr) 2020-01-31
KR101889392B1 (ko) 2018-08-17
US20200360345A1 (en) 2020-11-19
CA2827285C (en) 2019-05-07
EP2680829A1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
IN2014DN09434A (es)
NZ704247A (en) Compositions and treatment for eye diseases and disorders
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
UA117154C2 (uk) Антагоністи s1p3
MX2015008187A (es) Inhibidores de alk deuterados.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
BR112015019524A2 (pt) tratamento de combinação
NZ708821A (en) Lfa-1 inhibitor formulations
PH12015501538A1 (en) Topical ocular analgesic agents

Legal Events

Date Code Title Description
FG Grant or registration